71 related articles for article (PubMed ID: 11086960)
41. [Hemopoietic stem cells and antitumoral drugs. 1. Variations of in vitro and in vivo colony forming cells following single dose administration of cyclophosphamide, vinblastine and azathioprine (author's transl)].
Pannacciulli I; Ghio R; Bogliolo G; Massa G; Saviane A; Bianchi G
Haematologica; 1976 Dec; 61(4):432-8. PubMed ID: 828607
[No Abstract] [Full Text] [Related]
42. Lymphocytic recovery after experimental suppression of haemopoiesis in the rat.
Berger J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):599-603. PubMed ID: 6083933
[TBL] [Abstract][Full Text] [Related]
43. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
Lelieveld P; van Putten LM
Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
[TBL] [Abstract][Full Text] [Related]
44. [Recombinant hematopoietic growth factors in the treatment of various hematologic diseases].
Pawelski S
Acta Haematol Pol; 1991; 22(1):186-93. PubMed ID: 1823962
[No Abstract] [Full Text] [Related]
45. Lithium and hematopoietic toxicity. I. Recovery in vivo of murine hematopoietic stem cells (CFU-S and CFU-Mix) after single-dose administration of cyclophosphamide.
Gallicchio VS
Exp Hematol; 1986 Jun; 14(5):395-400. PubMed ID: 3709709
[TBL] [Abstract][Full Text] [Related]
46. Household insecticides and blood diseases.
Machemer L; Lorke D
Lancet; 1982 Aug; 2(8294):381. PubMed ID: 6124777
[No Abstract] [Full Text] [Related]
47. [APROPOS OF THE USE OF CYCLOPHOSPHAMIDE IN 28 CASES OF MALIGNANT BLOOD DISEASES].
MULLER B
Lyon Med; 1965 Mar; 213():897-916. PubMed ID: 14312669
[No Abstract] [Full Text] [Related]
48. Fine and Gray or Cox model?
Arcuri LJ; Souza Santos FP; Perini GF; Hamerschlak N
Blood Adv; 2024 Mar; 8(6):1420-1421. PubMed ID: 38191679
[No Abstract] [Full Text] [Related]
49. Review of the Cox hematotoxicity model.
Heaney ML; Nimer SD
J Toxicol Environ Health A; 2000 Nov; 61(5-6):539-41. PubMed ID: 11086965
[No Abstract] [Full Text] [Related]
50. Hematopoietic stem cells.
Quesenberry P; Levitt L
N Engl J Med; 1979 Oct; 301(14):755-61. PubMed ID: 384246
[No Abstract] [Full Text] [Related]
51. Comments on the Cox model of cyclophosphamide hematotoxicity.
Krishnan K
J Toxicol Environ Health A; 2000 Nov; 61(5-6):511-4. PubMed ID: 11086960
[No Abstract] [Full Text] [Related]
52. From cyclophosphamide hematotoxicity to modeling cancer.
Luebeck EG
J Toxicol Environ Health A; 2000 Nov; 61(5-6):515-20. PubMed ID: 11086961
[No Abstract] [Full Text] [Related]
53. Biologically based risk assessment model for cyclophosphamide hematotoxicity in animal species: concluding comments.
Andersen ME; Krewski D
J Toxicol Environ Health A; 2000 Nov; 61(5-6):543-52. PubMed ID: 11086966
[No Abstract] [Full Text] [Related]
54. A biomathematical model of cyclophosphamide hematotoxicity.
Cox LA
J Toxicol Environ Health A; 2000 Nov; 61(5-6):501-10. PubMed ID: 11086959
[No Abstract] [Full Text] [Related]
55. Comments on a biochemical model of cyclophosphamide hematotoxicity.
Portier CJ; Parham FM
J Toxicol Environ Health A; 2000 Nov; 61(5-6):525-8. PubMed ID: 11086963
[No Abstract] [Full Text] [Related]
56. A clinician's comments on the cyclophosphamide hematotoxicity biologically based risk assessment model.
Atkins HL
J Toxicol Environ Health A; 2000 Nov; 61(5-6):529-38. PubMed ID: 11086964
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
